92 items found

Tags: 110309 Infectious Diseases CI Cancer Cell Biology RCT Science Policy

Filter Results
  • dataset

    Methodological quality assessment of included studies.

    Methodological quality assessment of included studies.
  • dataset

    Results of quality assessment using Newcastle-Ottawa scale for cohort studies.

    Results of quality assessment using Newcastle-Ottawa scale for cohort studies.
  • dataset

    Forest plot diagram showing the effect of TXA on post-operative blood loss.

    The black diamond signifies that the mean difference is in favour of TXA. The size of each square depends on the weight of each study. A green square is given to continuous...
  • dataset

    Demographic characteristics and baseline parameters of included studies in th...

    Demographic characteristics and baseline parameters of included studies in this study.
  • dataset

    r37980778c78--5f6b7c21d05113337723c1e54cf44b69

    Baseline characteristics of patients in the included Randomized Clinical Trials.
  • dataset

    Risk of bias according to revised Cochrane risk-of-bias tool for randomized t...

    Risk of bias according to revised Cochrane risk-of-bias tool for randomized trials.
  • dataset

    r37980778c78--3d91728437141a60a66530ea8374b39a

    BackgroundThe effects of neuromuscular blocking agents (NMBAs) on adult patients with acute respiratory distress syndrome (ARDS) remain unclear. We performed a meta-analysis of...
  • dataset

    r37980778c78--f97206ad2b9b0c9532b241d28f976a09

    Subgroup analyses of the efficacy endpoints.
  • dataset

    Characteristics of included trials.

    PI, plaque index; GI, gingival index; PPD, probing pocket depth; CAL, clinical attachment loss; GR, gingival recession; BOP, bleeding on probing; NA, not available; CHX,...
  • dataset

    Baseline characteristics of participants.

    Data are presented as mean±SD, median (interquartile range) or percent. Chi-square test for categorical variables, the unpaired t test or Mann-Whitney U test for continuous...
  • dataset

    Summary of data on serological response rates of interventions at 6-month fol...

    Summary of data on serological response rates of interventions at 6-month follow-up.
  • dataset

    Summary of the results.

    The proteasome inhibitor MG-132 down-regulates (−) the ubiquitin-proteasome pathway (UPP). AMPK-activator AICAR and proteasome inhibitor MG-132 co-treatment activates (+) the...
  • dataset

    r37980778c78--e592b4284520a99abb904b8e48c4297e

    Characteristics of the 16 included studies.
  • dataset

    r37980778c78--7588184c0022082e19ece4312d3aaed8

    The black diamond signifies that the mean difference is in favour of TXA. The size of each square depends on the weight of each study. A green square is given to continuous...
  • dataset

    Main characteristics of studies included in the meta-analysis of the effects ...

    Main characteristics of studies included in the meta-analysis of the effects of omega-3 fatty acids on proteinuria among patients with diabetes.
  • dataset

    Ibrutinib increases the risk of hypertension and atrial fibrillation: Systema...

    IntroductionIbrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell...
  • dataset

    Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithel...

    ObjectiveTo assess whether neoadjuvant chemotherapy (NACT) is superior to primary debulking surgery (PDS) with regard to optimal cytoreduction, peri-operative morbidity,...
  • dataset

    Main characteristics of all of the included studies.

    Main characteristics of all of the included studies.
  • dataset

    Effectiveness of screening for atrial fibrillation and its determinants. A me...

    BackgroundMany atrial fibrillation patients eligible for oral anticoagulants are unaware of the presence of AF, and improved detection is necessary to facilitate...
  • dataset

    Subgroup analyses of the efficacy endpoints.

    Subgroup analyses of the efficacy endpoints.